First Trust Health Care AlphaDEX Fund


Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

Цена последней сделки 110.4
Код ценной бумаги FXH
Полное наименование First Trust Health Care AlphaDEX Fund
Объем 1462000000
Изм за день, % 0.01
Комиссия 0.61
Дата основания May 08. 2007
Ссылка ссылка
Тип актива Equity
Индекс StrataQuant Health Care Index
Регион North America
Средний P/E 22.51
Дивиденды 0.61
5 летняя доходность 110.09
3 летняя доходность 53.35
Годовая доходность 33.40
Бета 0.91
Валюта usd

Топ эмитентов

Эмитент Доля, % P/BV P/S P/E EV/Ebitda
Moderna 2.77 23.12 73.91 -80
Biogen 2.19 3.88 3.09 11 9.16
Boston Scientific 2.07 3.31 5.08 14.89 69.29
HCA Healthcare 2.05 102.09 1.13 15.74 9.27
Cigna Corporation 1.97 1.48 0.46 9.14 8.97
NovoCure Limited 1.92 57.31 39.15 939.95 693.61
Guardant Health, Inc. 1.91 11.93 54.16 -60.64
Quest Diagnostics Incorporated 1.9 2.27 1.63 11.04 7.78
Alexion 1.88 2.86 5.49 55.76 10.45
Premier, Inc. 1.88 1.93 2.89 13.47 10.35
UHS 1.87 1.69 0.92 11.4 7.34

Похожие ETF

Описание First Trust Health Care AlphaDEX Fund

This ETF offers exposure to the U.S. health care sector, making it one of many options for accessing a corner of the market that is generally stable and can offer attractive dividends. Given the sector-specific focus, FXH likely doesn't deserve a core allocation, but may be useful as a means of implementing a tactical tilt towards the health care sector. FXH seeks to replicate an index that employs a unique strategy designed to generate excess returns relative to traditional cap-weighted benchmarks. The underlying AlphaDEX Index employs a quant-based screening methodology designed to identify stocks poised for outperformance. In return for exposure to this strategy, which has historically delivered impressive returns, investors can expect to pay a bit more; FXH's expense ratio is about 50 basis points higher than low cost options for health care exposure such as FHC and XLV. The unique index construction methodology has some other potential advantages; FXH maintains a much lower concentration of top holdings than do cap-weighted funds such as XLF. That means that performance isn't as dependent on a handful of large cap stocks, potentially giving a better way to access health care stocks. For those who believe in the merits of the AlphaDEX methodology and are willing to pay a little extra for a shot at alpha, FXH might be worth a closer look. Those looking to keep a cap on expenses and simply own the broader market have cheaper options available to them.